Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 731 to 740 of 881

TitleReference numberPublishedLast updated
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fractionTA388
Sapropterin for treating hyperphenylalaninaemia in phenylketonuriaTA729
Sarilumab for moderate to severe rheumatoid arthritisTA485
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal)TA960
Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)TA961
Secukinumab for treating active ankylosing spondylitisTA407
Secukinumab for treating active non-radiographic axial spondyloarthritisTA719
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935

Results per page

  1. 10
  2. 25
  3. 50
  4. All